Neurofibromatosis Type 2

Neurofibromatosis type 2 is the less common form of neurofibromatosis. This condition is typically characterized by the development of benign tumors called schwannomas that grow along the eighth cranial nerve, which is responsible for hearing and balance.

Neurofibromatosis type 2 usually causes hearing loss, tinnitus, and balance problems, particularly when negotiating uneven ground or walking in the dark. Many people with this condition also experience vision problems.

Neurofibromatosis Type 1 and Type 2 – Mayo Clinic

Features

Another form of neurofibromatosis is the condition schwannomatosis, which has features that commonly overlap with neurofibromatosis type 2. However, in schwannomatosis, the tumors develop anywhere in the body apart from the vestibular branch of the eighth cranial nerve. Pain is the main symptom of schwannomatosis, which develops as a schwannoma grows larger and starts to compress nerves.

In type 2 neurofibromatosis, the symptoms depend on where in the body the tumors develop. The tumors usually affect one ear at first but may eventually affect both ears. Less commonly, a person affected by vestibular schwannomas may experience vertigo-like symptoms, as if the environment around them is moving. Eventually the tumors can cause facial numbness, weakness in the tongue leading to slurring, and facial pain.

Other features of neurofibromatosis type 2 include non-vestibular schwannomas, cataracts, and meningiomas.

Epidemiology and cause

Neurofibromatosis type 2 is less common than type 1 neurofibromatosis and is reported in only about 1 in 35,000 live births. In around half of the cases, this condition is caused by a mutated gene that is passed on from a parent to their child.

In the other half of cases, the mutation develops sporadically in people with no family history of the condition. These patients can also pass the condition onto their offspring.

Diagnosis

A diagnosis of neurofibromatosis type 2 is based on the presence of clinical features of the disease, magnetic resonance imaging (MRI), hearing tests, vision tests, and a genetic test for the NF2 mutation. Prenatal testing can also be performed to check for this mutation and the most commonly used tests include chorionic villus sampling, and amniocentesis.

References

Further Reading

Last Updated: Apr 8, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, April 08). Neurofibromatosis Type 2. News-Medical. Retrieved on June 23, 2024 from https://www.news-medical.net/health/Neurofibromatosis-Type-2.aspx.

  • MLA

    Mandal, Ananya. "Neurofibromatosis Type 2". News-Medical. 23 June 2024. <https://www.news-medical.net/health/Neurofibromatosis-Type-2.aspx>.

  • Chicago

    Mandal, Ananya. "Neurofibromatosis Type 2". News-Medical. https://www.news-medical.net/health/Neurofibromatosis-Type-2.aspx. (accessed June 23, 2024).

  • Harvard

    Mandal, Ananya. 2023. Neurofibromatosis Type 2. News-Medical, viewed 23 June 2024, https://www.news-medical.net/health/Neurofibromatosis-Type-2.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify increased brain tumor risk with specific contraceptive use